Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia in Patients Receiving Myelosuppressive Treatment Regimens Requiring Platelet Transfusion Support.
Phase 3
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Neoplasms, Thrombocytopenia, Multiple Myeloma, Lymphoma, Malignant
Both
Neoplasms, Thrombocytopenia, Multiple Myeloma, Lymphoma, Malignant
Trial Information
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia in Patients Receiving Myelosuppressive Treatment Regimens Requiring Platelet Transfusion Support.
Inclusion Criteria:
- Patients must have solid tumors, lymphomas or multiple myeloma who are receiving
myelosuppressive treatment regimens requiring platelet transfusion support
Exclusion Criteria:
- Patients must not have active bleeding (exclusions do apply) or history of platelet
disorder
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention
Outcome Measure:
To evaluate the effectiveness of two schedules of intravenous rhTPO versus placebo as secondary prophylaxis in reducing the proportion of patients requiring platelet transfusion for severe chemotherapy-induced thrombocytopenia.
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
United States: Food and Drug Administration
Study ID:
98-OTPO-005
NCT ID:
NCT00037791
Start Date:
December 1999
Completion Date:
September 2002
Related Keywords:
- Neoplasms
- Thrombocytopenia
- Multiple Myeloma
- Lymphoma, Malignant
- Neoplasms
- Lymphoma
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Thrombocytopenia
Name | Location |
|---|---|
| Pfizer Investigational Site | Blendora, California 91740 |
| Pfizer Investigational Site | Houston, Texas 77030 |
| Pfizer Investigational Site | Shreveport, Louisiana 71103 |
